UnitedHealth Group Incorporated · Healthcare
Paid for today, but breaks on a small cut — or only looks over-priced at a 9% discount rate.
At a 3.8% margin the price requires 3.6% 3y revenue CAGR against 2.9% consensus, a cushion of -1.4pt versus a 0pt correction cut. Cushion is negative at the panel margin but turns positive 1pt lower in the discount rate, so it hangs on the rate and the margin. The fall coincides with the AI drop but is caused by CMS policy; judge it on policy.
Would recover if: the CMS rule (2026-11-18) moves into 2027 estimates and margin resets below 3.8%. We re-check this against analyst estimates every evening.
10 years, at a 4% margin analysts expect
+2.7%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
13 published targets
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 143% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Nov 21, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
At the price the stock sits 32% below the median of 13 published analyst targets ($402-$531), meaning the market is pricing sustained policy damage that every covering bank rejects.
The single question is whether the CMS anti-fraud/CRUSH rules and single-payer proposals permanently compress UnitedHealthcare's Medicare Advantage economics, or whether the 7.8-8.0% operating margin target survives; nothing wired here (consumer attention, segment revenue history) can measure regulatory cost-recovery or claims trend, so this is not testable with available data.
What the price refuses to pay for, and the full reconstruction, on the UNH quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names